Assessment of in vitro activity of the new triterpenoid antifungal, SCY-247, against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024

SCY-247, A SECOND-GENERATION TRITERPENOID ANTIFUNGAL DEMONSTRATES BROAD TISSUE DISTRIBUTION AND EFFICACY IN MURINE FUNGAL INFECTION MODELS

The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by Candida glabrata

SCY-247, a Novel Second-Generation IV/Oral Triterpenoid Antifungal, Demonstrates In vitro Activity Against Fungal Pathogens, Including Azole-Resistant Strains of Candida and Aspergillus

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis

SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL: IN VITRO ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION IN VIVO

A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans Antimicrobial Agents and Chemotherapy

A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates Antimicrobial Agents and Chemotherapy